Arcellx

How biotech companies are standing out during JPM Week
Medical Marketing and Media
Mon, 01/8/24 - 10:26 pm
Aurion
Arcellx
JPMHC 2024
Gilead’s Kite Expands Arcellx Pact with $285M Equity Investment, Upfront Cash
BioSpace
Wed, 11/15/23 - 11:11 am
Gilead Sciences
Kite Pharma
Arcellx
CART-ddBCMA
lymphoma
FDA lifts clinical hold on Gilead's CAR-T as Arcellx sheds light on reason for patient death
Fierce Biotech
Tue, 08/15/23 - 10:12 am
Gilead Sciences
Arcellx
CAR-T
cell therapy
FDA
FDA places clinical hold on Arcellx’s multiple myeloma therapy trial
Clinical Trials Arena
Tue, 06/20/23 - 09:57 am
Arcellx
CAR-T
CART-ddBCMA
relapsed or refractory multiple myeloma
FDA
clinical trials
Gilead lands new cell therapy for Kite in $225M Arcellx deal
Fierce Biotech
Fri, 12/9/22 - 10:37 am
Gilead Sciences
Kite Pharma
Arcellx
clinical trials
Multiple Myeloma
cell therapy
JNJ
Legend Biotech
ASCO 2022 – Carvykti casts a long shadow
EP Vantage
Mon, 06/6/22 - 10:01 am
ASCO 2022
Carvykti
CAR-T
Arcellx
Gracell
Oricell
Multiple Myeloma
Biopharma flotations tank in the first quarter
EP Vantage
Thu, 04/7/22 - 10:11 am
Amylyx Pharmaceuticals
CinCor Pharma
Arcellx
Vigil Neuroscience
AN2 Therapeutics
IPOs
Arcellx’s IPO raises $124M to fuel chase of better CAR T-cell therapy for cancer
MedCity News
Tue, 02/8/22 - 09:53 am
Arcellx
IPOs
CAR-T
funding
cell therapy
Multiple Myeloma
Arcellx raises $124M in Wall Street debut to bankroll study of multiple myeloma CAR-T
Fierce Biotech
Fri, 02/4/22 - 11:01 am
Arcellx
IPOs
Multiple Myeloma
Pushing to Improve Immunotherapies, Arcellx Raises $85 Million in Series B
BioSpace
Thu, 10/3/19 - 10:13 pm
Arcellx
immunotherapy